Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
Sign Up to like & getrecommendations! Published in 2019 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2018.07.005
Abstract: OBJECTIVE To study acceptance rate and factors influencing acceptance of the switch from originator etanercept (Enbrel©) to biosimilar etanercept (SB4, Bénépali©) in patients with rheumatic disease. METHODS Patients with a well-controlled rheumatic disease consulting in… read more here.
Keywords: acceptance rate; switch originator; rate; acceptance ... See more keywords
THU0157 ‘SWITCH ME IF YOU CAN’ – REAL LIFE EXPERIENCE OF SWITCHING TO BIOSIMILAR DRUGS FROM GARTNAVEL GENERAL HOSPITAL, GLASGOW, UK
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2561
Abstract: Background: Rheumatology has entered the era of biosimilar drugs. Compared with the original approved biological drug, a biosimilar has highly similar physiochemical characteristics and biological activity1. There is also equivalent efficacy and no clinically meaningful… read more here.
Keywords: biosimilar adalimumab; gartnavel general; general hospital; rheumatology ... See more keywords